Centauri Therapeutics Limited: Centauri Therapeutics Strengt

Dr Jennifer Schneider appointed CEO, Dr Helen Bright joins as VP of Research Development, and Professor David Roblin will Chair the Board of Directors Senior appointments support acceleration

Related Keywords

United States , Michigan , America , Pamela Brown , Michelle Ricketts , Sosei Heptares , Jennifer Schneider , Mike Westby , Kostenloser Wertpapierhandel , David Roblin Frcp Fmedsci , David Roblin , Glaxosmithkline , Global Antibiotic Research Development Partnership , Impact Fund , Research Development , Boehringer Ingelheim Venture Fund , University Of Michigan , Centauri Therapeutics Limited , Pfizer , Astrazeneca , University Of Notre Dame , Master Of Public Health In Epidemiology , Zyme Communications , Professor Of Medicine At Swansea University , Newcastle Upon Tyne University , International Health , Francis Crick Institute , Novo Holdings , Professor David Roblin , Therapeutics Limited , Chief Executive Officer , Vice President , Executive Officer , Molecular Biology , Notre Dame , Public Health , Helen Bright , Medicines Discovery Catapult , Scientific Translation , Translational Medicine , Non Executive Director , Relation Therapeutics , Centauri Therapeutics , Chief Scientific Officer , Professor Roblin , Centauri , Herapeutics , Imited , Trengthens , Senior , Leadership , Team , Ith , Three , Appointments ,